Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile

Journal of Psychopharmacology
Tsuyoshi HiroseToshitaka Nabeshima

Abstract

The antipsychotic efficacy of aripiprazole is not generally associated with extrapyramidal symptoms, cardiovascular effects, sedation or elevations in serum prolactin that characterize typical or atypical antipsychotics. The aim of this study was to clarify the mechanism of action of aripiprazole that underlies its favourable clinical profiles. The preclinical efficacy and side-effect profiles of aripiprazole were evaluated using several pharmaco-behavioural test systems in mice and rats, both in vivo and ex vivo, and compared with those of other conventional and atypical antipsychotics. Each of the antipsychotics induced catalepsy and inhibited apomorphine-induced stereotypy. The catalepsy liability ratios for these drugs were 6.5 for aripiprazole, 4.7 for both olanzapine and risperidone. The ptosis liability ratios for aripiprazole, olanzapine and risperidone were 14, 7.2 and 3.3, respectively. Aripiprazole slightly increased DOPA accumulation in the forebrain of reserpinised mice, reduced 5-HTP accumulation at the highest dose and exhibited a weaker inhibition of 5-methoxy-N,N-dimethyl-tryptamine-induced head twitches. Aripiprazole did not inhibit physostigmine- or norepinephrine-induced lethality in rats. In conclusion, ari...Continue Reading

References

Jan 1, 1990·Annals of the New York Academy of Sciences·M HamonL Schechter
Mar 1, 1973·European Journal of Pharmacology·B Costall, R J Naylor
Jan 1, 1983·Psychopharmacology·M J DeniardF V DeFeudis
Sep 1, 1984·Naunyn-Schmiedeberg's Archives of Pharmacology·K P Minneman, P W Abel
Jan 1, 1994·The Journal of Neuropsychiatry and Clinical Neurosciences·D R WeinbergerK F Berman
Apr 1, 1996·The American Journal of Psychiatry·S Kapur, G Remington
Jan 1, 1997·Life Sciences·P Seeman, S Kapur
Jan 1, 1997·Harvard Review of Psychiatry·R L Borison
Mar 13, 1999·The Journal of Clinical Psychiatry·E HowanitzM F Losonczy
May 18, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C P LawlerR B Mailman
Oct 12, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J S SprouseS H Zorn
Jul 8, 2000·Proceedings of the National Academy of Sciences of the United States of America·P Seeman, S Kapur
Mar 16, 2001·Expert Opinion on Pharmacotherapy·B C Lund, P J Perry
Jun 8, 2001·Proceedings of the National Academy of Sciences of the United States of America·M F EganD R Weinberger
Dec 18, 2001·Biological Psychiatry·P F Buckley
Dec 19, 2001·International Journal of Geriatric Psychiatry·J S KennedyA Breier
Jun 14, 2002·European Journal of Pharmacology·Shaun JordanC Anthony Altar
Jun 18, 2002·The Journal of Pharmacology and Experimental Therapeutics·Kevin D BurrisPerry B Molinoff

❮ Previous
Next ❯

Citations

Mar 27, 2012·European Child & Adolescent Psychiatry·Eiji Kirino
Dec 4, 2009·Primary Care Companion to the Journal of Clinical Psychiatry·J Sloan Manning, Susan L McElroy
Dec 24, 2013·Future Medicinal Chemistry·Pawel ZajdelAnna Wesolowska
Jan 2, 2009·The British Journal of Psychiatry : the Journal of Mental Science·Allan H YoungRaymond Sanchez
Jun 27, 2009·Neuropsychiatric Disease and Treatment·David J Muzina
Dec 22, 2006·Expert Review of Neurotherapeutics·Margarita García-AmadorEduard Vieta
May 14, 2008·Expert Opinion on Pharmacotherapy·Rajnish Mago
Jan 25, 2011·Expert Opinion on Pharmacotherapy·Andrea FagioliniFrancesco Casamassima
May 16, 2007·Expert Opinion on Investigational Drugs·Martyn Wood, Charlie Reavill
Feb 21, 2013·The American Journal of Drug and Alcohol Abuse·Ramakrishna NirogiRenny Abraham
Oct 2, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Yoshiteru TakekitaToshihiko Kinoshita
Oct 3, 2015·The International Journal of Neuropsychopharmacology·Chris A OosterhofPierre Blier
Feb 16, 2010·Clinical Therapeutics·Emmanuel Stip, Valérie Tourjman
Dec 5, 2008·Journal of Psychosocial Nursing and Mental Health Services·Roy R Reeves, James C Brister
Feb 26, 2009·Schizophrenia Research·Jun-Sheng WangC Lindsay Devane
Apr 9, 2009·Pharmacology, Biochemistry, and Behavior·Su-xia LiLin Lu
Jun 27, 2009·General Hospital Psychiatry·Prasenjit RayS Haque Nizamie
Oct 14, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Mong-Liang LuChun-Hsin Chen
Sep 4, 2007·Schizophrenia Research·C RabinS J Siegel
Nov 20, 2012·Basic & Clinical Pharmacology & Toxicology·Thercia G VianaFabricio A Moreira
Dec 18, 2014·Psychogeriatrics : the Official Journal of the Japanese Psychogeriatric Society·Eiji Kirino
Jun 30, 2006·Biological Psychiatry·Matthew W FeltensteinRonald E See
Dec 22, 2005·The Journal of Medical Investigation : JMI·Tsuyoshi Hirose, Tetsuro Kikuchi
Jan 17, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Makoto IshitobiYuji Wada
Sep 12, 2013·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Bong Ju LeeYoung Hoon Kim
Sep 17, 2011·European Psychiatry : the Journal of the Association of European Psychiatrists·J PeuskensE Constant
Mar 1, 2015·European Journal of Pharmacology·Fabricio A Moreira, Jeffrey W Dalley

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
David A ShapiroRichard B Mailman
The Journal of Pharmacology and Experimental Therapeutics
Kevin D BurrisPerry B Molinoff
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Sridhar NatesanShitij Kapur
© 2021 Meta ULC. All rights reserved